(Q36887923)

16 August 2017

1 reference

title

Emerging treatments in multiple sclerosis: azathioprine and mofetil (English)

1 reference

16 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

C Confavreux

1

1 reference

16 August 2017

T Moreau

series ordinal

2

1 reference

16 August 2017

language of work or name

1 reference

1 July 1996

1 reference

Multiple Sclerosis Journal

16 August 2017

published in

1 reference

16 August 2017

volume

1

1 reference

16 August 2017

issue

6

1 reference

16 August 2017

page(s)

379-384

1 reference

Multiple sclerosis: immunological findings and possible implications for therapy

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100620

New perspectives on immunointervention in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100620

Advances in the understanding and treatment of multiple sclerosis. Boston, Massachusetts, USA, 28-29 October 1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100620

Mechanisms of Action of Mycophenolic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100620

The purine path to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100620

Overview of azathioprine treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100620

A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100620

The efficacy of azathioprine in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100620

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100620

Magnetic resonance imaging in the evaluation of treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100620

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100620

Malignant Neoplasms Following Cardiac Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100620

Nonmelanoma cancers of the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100620

Occurrence of Non-Hodgkin's Lymphoma after Therapy for Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100620

Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100620

Azathioprine, a genotoxic agent to be considered non-genotoxic in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100620

A re-examination of the genotoxicity and carcinogenicity of azathioprine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100620

Long-term safety of azathioprine therapy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100620

New immunosuppressive treatment in transplantation medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100620

10.1177/135245859600100620

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference